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ABSTRACT 
 
This study determined medical service utilization and costs associated with 
switching to risperidone from previous treatment with typical antipsychotic 
agents.  62 adult outpatients diagnosed with schizophrenia were identified 
from pharmacy records, with complete information regarding medical 
service utilization for one year before and after treatment with risperidone. 
Information on hospitalization, use of day care hospital, electroconvulsive 
therapy, emergency department, outpatient clinic services and functional 
parameters were collected. Cost of treatment, cost of unemployment and cost 
of lost productivity due to suicide were calculated. The results showed 
significant fewer hospitalization days, ECT sessions and emergency 
department visits were observed one year after switching to risperidone 
(p<.05). The total treatment costs associated with risperidone after one year 
was 88.8% higher than costs during the previous year of treatment with 
typical antipsychotic agents.  
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Introduction 
  
Schizophrenia is a serious mental illness. 
For majority of patients it is a lifetime 
condition, characterized by intermittent 
episodes of hospitalization due to relapse or 
acute symptom exacerbation(1, 2). The 
nature and course of the disorder impose 
significant social and economic burden. 
Relapse is costly, with hospitalization 
accounting for a substantial portion of 
healthcare expenses. Periods of acute 
episodes are strongly linked with  
 
unemployment. Other costs include loss of 
productivity among unpaid family 
caregivers(3). In UK, the estimated of direct 
cost of treatment and care of schizophrenia 
was about 2 billion pounds in 2004/05. The 
burden of indirect costs was amounting to 
nearly 4.7 billion pounds. The cost of lost 
productivity due to unemployment, absence 
from work and premature mortality of 
patients was 3.4 billion pounds.(4) In the 
U.S., of the estimated direct costs in 2002 of 
schizophrenia treatment amounted to 
US$22.7 billion. The indirect costs, 
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including losses due to unemployment were 
$32.4 billion.(5) The hospitalization cost 
associated with antipsychotic nonadherence 
was much higher ranging from $1392 
million to $1826 million in 1995(6).  
   
Antipsychotic pharmacotherapy continues to 
play an important role in reducing acute 
symptoms, improving functioning and 
preventing relapse among patients with 
schizophrenia(7-9). Risperidone, an atypical 
antipsychotic agent, has demonstrated 
efficacy in improving schizophrenia 
symptoms in both short and long-term 
studies(10, 11). It also has been associated 
with a relatively smaller risk of relapse at 1 
year follow-up compared with haloperidol 
(1, 12-14). However, the higher acquisition 
cost of this drug compared to typical 
antipsychotic medications remains a limiting 
factor to its use.(15-17)  
  
Nevertheless it has been suggested that net 
savings due to reductions in service 
utilization mediated by risperidone use may 
compensate for the drug’s high acquisition 
cost(18-21). Comparison of hospitalization 
rates before and after initiation of 
risperidone in clinical trials has shown 
reduction in number of days hospitalized by 
as much as 31% – 73% (22-27). In the 
systematic review by Hudson and colleagues 
of 22 economic evaluation studies on novel 
antipsychotic agents(28), ten retrospective 
studies compared costs associated with use 
of risperidone versus conventional 
antipsychotic drugs. One study estimated 
costs of clinical data gathered in an 
experimental setting(29), while 9 studies 
used data gathered from patient records(29-
37) . Decreased in total costs were noted in 5 
studies(29, 30, 33, 36, 37), while increased 
in total costs were reported in 4 studies (31, 
32, 34, 35). Using scores on clinical 
improvement as measures of effectiveness 
and decrease in service utilization as proxy 
indicators of improvement, three studies 
documented improved effectiveness and 
lower total costs associated with risperidone 
use(29, 30, 33). The review also noted that 
all of the 7 studies that used simulation 
models to estimate costs associated with use 
of atypical antipsychotic drugs, indicated 
cost advantages(28).  
 
However these studies dealt primarily with 
patients in developed countries. Data on the 
economic impact of schizophrenia in 
developing countries was limited. Given the 
economic burden of schizophrenia, 
evaluating the costs associated with use of 
particular drugs was really vital. The 
objectives of this study was to compare 
medical service utilization and costs 
associated with switching to risperidone 
from previous treatment with typical 
antipsychotic agents among outpatients in 
the University of Malaya Medical Center. 
 
Materials and Methods 
 
Study Design and study subjects 
 
This was a cross-sectional study of before 
and during risperidone treatment. The 
eligible study subjects were outpatients, 
aged 18 years and above and have a 
diagnosis of schizophrenia according to 
DSM IV criteria. All outpatients treated with 
oral risperidone from January 2001 to 
January 2005, were identified from the 
pharmacy records of the University of 
Malaya Medical Center (UMMC). The 
UMMC is the oldest teaching hospital and 
acts as a referral center for Klang Valley 
(Kuala Lumpur), Malaysia. It attends to 
approximately 24,000 psychiatric 
outpatients and 800 psychiatric inpatients a 
year.  
 
The selection criteria was each patient must 
have been treated with the same typical 
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antipsychotic agent for at least one year. The 
patients later were switched to oral 
risperidone and maintained as outpatient for 
at least one year. The follow-up information 
for at least one year must be available from 
the medical records for each type of 
antipsychotic drug treatment. 
  
Patients with other than Axis I diagnoses, 
less than one year of treatment with 
risperidone, taking atypical antipsychotic 
agents other than risperidone, or with 
inadequate follow-up data were excluded 
from the study.  
 
Data collection  
 
For each patient, a structured questionnaire 
was used to collect data for the last 12-
month period prior to risperidone treatment, 
which was during treatment with a 
conventional antipsychotic drug, and for the 
12-month period immediately after initiation 
of risperidone. All information was obtained 
from patients’ medical record. The 
questionnaire was divided into three 
sections; demographic characteristics, 
medical service utilization and functional 
parameters during treatment.   
 
The first section was to describe the 
demographic data of the study population, 
i.e. age, sex, race, education level and 
marital status. The second section was 
regarding medical service utilization for 
both treatment periods, mainly to describe 
the number of days hospitalized, number of 
electroconvulsive therapy sessions 
undergone, number of days spent in day care 
hospital, number of emergency department 
visits, number of scheduled clinic visits and 
number of unscheduled clinic visits. Number 
of scheduled clinic visits attended was used 
as an indicator of compliance to therapy. 
The third section was regarding functional 
parameters which included the use of 
institutional residential care, employment, 
showing of violent episodes requiring 
restraint, attempted suicides at least once 
and police reports against the patient at least 
once. The third section was used as 
indicators of indirect consequences of 
schizophrenia. Ethical approval was 
obtained from UMMC Ethical Committee.  
 
Cost for treatment with typical 
antipsychotics and risperidone  
 
The cost stated was the fee that needed to be 
paid by patients after medical service 
utilization. Cost of medical service 
utilization was calculated separately for 
treatment with typical antipsychotics and 
risperidone. It was the total cost of each type 
of medical services. Medical service 
utilization cost for hospitalization was 
computed by multiplying total admission 
day and hospitalization charges, whereas 
day care hospital cost was obtained by 
multiplying total day and day charges. Other 
medical service utilization was derived by 
multiplying the frequency of utilization and 
the charges of each service. Cost estimation 
for treatment was obtained by summation of 
cost of medical services and cost of 
medication. The hospital charges of medical 
service in UMMC were based on 2005 rates.  
 
Cost estimation in lost of productivity   
 
The functional parameters measured during 
treatment were employment status and 
attempted suicide. A further analysis was 
done to quantify the economic loss due to 
unemployment and suicide attempt using 
procedures described in a previous study 
(38, 39) The employment rate loss due to 
schizophrenia was calculated based on the 
difference between employment rates in the 
general population, reported by Department 
of Statistics, Malaysia in 2005(40) and 
employment rates for each antipsychotic 
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therapy, later multiply with monthly per 
capita income in 2005. Economic loss of 
suicide was assessed in terms of lost of 
employment, with the assumption that there 
would be lost of productivity for 6 months 
period in view of recovery from injury and 
rehabilitation. (39)The calculation of lost 
productivity due to suicide equal to attempt 
rate multiply by employment rate for each 
antipsychotic multiply 6-montly per capita 
income. The per capita income RM18,040 
was used based on report by the Department 
of Statistics, Malaysia in year 2005(40, 41).           
 
Statistical Analysis             
 
Raw data obtained were coded and entered 
into Statistical Package for Social Sciences 
(SPSS) Version 15.0. For categorical 
variables, they were described in the form of 
frequencies and percentages. For continuous 
variables, they were summarized and 
described as means, standard deviations, 
median and range.  
Differences in characteristics between 
groups were compared using Chi-square 
tests for categorical variables. 2-tailed paired 
t test was used for continuous variables and 
Wilcoxon Singed Ranks test was used for 
skewed distribution. Subsequently the 
continuous variables were recategorised and 
further tested by Pearson’s Chi-square test. 
An alpha level of 0.05 was set for all 
analyses. 
 
Results  
 
Out of 400 patients that have been screened, 
who were initially on typical antipsychotic 
medication and later switched to risperidone, 
only 62 patients fulfilled the selection 
criteria. Characteristics of selected patients 
were shown in Table 1. 
 
From Table 1, 56.5% were female patients; 
majority was between 20 to 59 years old 
(89%), which was also productivity age 
group. There was no statistically significant 
difference between the mean age of male 
and female patients. Further stratification 
analysis showed more female patients 
(30.6%) were married as compared to the 
males (12.9%). However, the difference was 
not statistically significant.  
 
Table 1. Characteristics of patients (n = 62) 
Variable n (%) 
Gender   
Male 27 (43.5) 
Female 35 (56.5) 
Age group   
20-29 6  (9.7) 
30-39 12 (19.4) 
40-49 23 (37.1) 
50-59 14 (22.6) 
60-69 4 (6.5) 
70 and above 3 (4.8) 
Race   
Malay 6 (9.7) 
Chinese 46 (74.2) 
Indian 10 (16.1) 
Level of Education   
No formal education 3 (4.8) 
Primary 13 (21.0) 
Secondary 38 (61.3) 
Tertiary  8 (12.9) 
Marital Status   
Single 32 (51.6) 
Married 27 (43.5) 
Divorced 3 (4.8) 
 
 
Data on medical service utilization for 
typical antipsychotic medication and 
risperidone were shown in Table 2. Overall 
duration for hospital stay for risperidone was 
shorter and less frequent visit for multiple 
hospital services compared to typical 
antipsychotics. The number of patients 
hospitalized at least once declined from 17 
patients during typical antipsychotic 
medication, to only 3 patients after the first 
year of treatment with risperidone. During 
the 1-year period of treatment with typical 
antipsychotic drugs, the cumulative number 
of days spent as in-patient was 372 days. 
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This would also equivalent to an average 
hospital stay of 6.0 + 2.4 days per patient 
during typical antipsychotic medication. 
During treatment with risperidone, 
hospitalization decreased to 51 days and the 
reduction in the number of days was 86%. 
 
 
Table 2. Comparison between typical antipsychotic medication and risperidone for medical service 
utilization, n=62 
Index of Service Utilization  
Typical 
antipsychotic 
Risperidone  p  
Hospitalization(day)    <0.001* 
Median  0 0   
Range  0 - 83  0 - 28    
Total 372 51   
No. of admitted patients  n(%) 17 (27.4) 3 (4.8)   
Electroconvulsive therapy (ECT) sessions    0.017* 
Median  0 0   
Range  0 - 8  0   
Total 45 0   
No. of patients required ECT n(%) 7 (11.3) 0   
Day care hospital(day)    0.107 
Median  0 0    
Range  0 - 68  0 - 63    
Total 196 96   
No. of day care patients  n (%) 7 (11.3) 3 (4.8)   
Emergency department visits    0.007* 
Median  0 0   
Range  0 - 3  0 - 1    
Total 20 4   
No. of patients visited emergency 
department  n(%) 
 
13 (21.0) 4 (6.5)  
 
Outpatient clinic visits (unscheduled visit)    0.883 
Median  0 0   
Range  0 - 7  0 - 5    
Total 52 53   
No. of patients visited unscheduled clinic   
n(%) 
29 (46.8) 27 (43.5)  
 
Outpatient clinic visits (scheduled follow-up)    <0 .001** 
Mean(SD) 3.02(1.49) 4.0(1.93)   
Median (Range)  3 (0 – 6)  4 (0 – 10)    
Total 187 248   
No. of patients visited scheduled clinic 
(n,%) 
58 (93.5%) 58 (93.5%)  
 
*Statistically significantly with Wilcoxon Signed RanksTest  
**Statistically significantly with Paired t Test  
 
The most remarkable finding was the use of 
electroconvulsive therapy (ECT), as none of 
patients on risperidone required the therapy.  
The visit to emergency department has also 
significantly reduced with risperidone. The 
proportion of patients making an 
unscheduled outpatient clinic visit at least 
once was almost similar during typical 
antipsychotic drugs and after changing to 
risperidone. However, in terms of 
compliance with scheduled outpatient clinic 
visits, the data showed significantly 
increased attendance during treatment with 
risperidone.( p<0.05)  
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The distribution of patients on functional 
parameters in Table 3 showed there was 
improvement in functioning with risperidone 
treatment compared to typical antipsychotic 
drugs. It also noted that during treatment 
with risperidone, employment increased by 
80% and the violent behaviors as indicated 
by needed for restraint decreased by 82%. In 
addition, there were no reports of suicide 
attempts and problems with the law during  
risperidone treatment, compared with 
reports of attempted suicide among 5 
patients and documented legal problems 
among 7 patients during treatment with 
typical antipsychotic agents. Economic loss 
related to unemployment and suicide 
attempts with typical antipsychotic drugs 
was RM 403,374 per month, while treatment 
with risperidone had lower cost at RM 
79,677 per month.    
 
 
 
Table 3. Distribution of patients on functional parameters, cost of unemployment and suicide during 
treatment with typical antipsychotic drugs and risperidone, n=62 
 
 
Typical antipsychotic Risperidone  
n % n % 
Residing in nursing home 3 42.8 4 57.2 
Employed 15 35.7 27 64.3 
Showing violent behavior requiring restraint 11 84.2 2 15.8 
Attempted suicide at least once 5 100.0 0 0 
Reported to police at least once 7 100.0 0 0 
Employment rate  24.2  43.5 
Suicide attempt rate  8.1  0 
Cost (RM)     
Unemployment/per month  108,691  79,677 
Lost productivity due to suicide/6 month  1,768,100  0 
 
The employment rate loss due to schizophrenia = the employment ratea – employment rate for each antipsychotics therapy 
Lost productivity due to suicide = attempt rate x employment rate for each antipsychotic therapy x 6-monthly income  
aThe employment rate for general population was 96.5% in 2005(From Department of Statistics, Malaysia) 
 
 
Costs associated with each treatment were 
shown in Table 4. Reduction in costs due to 
decrease in frequency of utilization were 
noted for most services. After risperidone 
initiation, the most substantial cost reduction 
was observed in hospitalization expenses. 
There was  
 
 
 
 
 
 
86.3% decreased in cost, representing a 
cumulative saving of RM 25,680 for the 
study subjects in the first year of risperidone 
treatment. This can be translated as an 
average saving in hospitalization of RM 
414.19 per patient for 1 year of risperidone 
treatment.  
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Table 4. Comparison of costs during treatment with typical antipsychotic drugs and risperidone, n=62 
 
Service Category 
Hospital 
Charges  
(RM) 
Typical antipsychotic 
 
Risperidone 
Difference   Frequenc
y 
Total(R
M) 
Frequency 
Total(R
M) 
Hospitalization¶ 80 372 29,760  51 4,080 -25,680 
Electroconvulsive therapy 175 45 7,875  0 0 -7,875 
Day care hospital ¶ 35 196 6,860  96 3,360 -3,500 
Emergency department services 50 20 1,000  4 200 -800 
Outpatient clinic services 35 239 8,365  301 10,535 +2,170 
Scheduled visit 35 187 6,545  248 8,680  
Unscheduled visit 35 52 1,820  53 1,855  
Medical service utilization cost   53,860   18,175 -35,685 
Antipsychotic medication 
Typical antipsychotic 
Risperidone  
 
744* 14,880 
 
 
 
744* 
 
 
111,600 
 
 
+96,720 
20/month 
150/month 
Total treatment cost   68,740   129,775 +61,035 
* 62 patients for 12 months treatment  
¶ the frequency for hospitalization and day care hospital counted as day  
 
The increased number of scheduled 
outpatient clinic visits has shown the 
improvement in compliant with the follow 
up. Cumulative 1-year cost for outpatient 
clinic services increased from RM 8,365 
during treatment with typical antipsychotic 
drugs to RM 10,535 during risperidone 
medication. As for the actual expenditure of 
antipsychotic medication, the cost for typical 
antipsychotic drugs and risperidone were 
approximately RM 5 and RM 300 per month 
respectively. However, patients were 
charged for RM 20 for typical antipsychotic 
drugs and RM 150 for risperidone. In one 
year, the charges per patient for typical 
antipsychotic drugs were RM 240 and RM 
1,800 for risperidone.    
 
In term of total medical service utilization 
cost for risperidone, there was 66.3% 
decreased in cost as compared to typical 
antipsychotic drugs. However with the 
higher charges on risperidone, the overall 
total treatment cost after switching to 
risperidone increased by 88.8%. The 
cumulative total treatment cost during 
treatment with typical antipsychotic drugs at 
RM 68,760 (RM 1,108.71 per patient), and 
RM 129,775 (RM 2,093.15 per patient) 
during treatment with risperidone.  
   
Discussion 
 
In many studies, atypical antipsychotic 
drugs had been proven to have better 
effectiveness compared to typical 
antipsychotics(42, 43). For this study, 62 
outpatients with history of previous 
treatment with typical antipsychotic drugs, 
showed significantly fewer days for 
hospitalization, less Electroconvulsive 
Therapy(ECT) sessions, emergency 
department visits, after one year switching 
to risperidone. The total treatment cost was 
88.8% higher after 1 year of risperidone 
treatment compared to treatment with 
typical antipsychotic drugs.  
  
Some studies have shown a similar trend for 
increased costs with risperidone use (32-35), 
while other studies have shown contrary 
findings(31, 44). The reason for higher cost 
of risperidone for this study was due to 
prescribing of original drug for risperidone 
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and generic drug for typical antipsychotics. 
Although the reduction in expenses 
associated with these lower utilization rates 
could compensate for the acquisition cost of 
risperidone, the real treatment cost was 
much higher as the price of risperidone was 
double from what has been paid by the 
patients.  
 
In this particular study however, the 
increased in total treatment cost with 
risperidone use was observed despite 
substantially lower service utilization costs. 
This suggested that antipsychotic medication 
expenses in developing countries account 
for a greater proportion of total direct costs, 
as opposed to developed countries. A cost-
of-illness study of schizophrenia in Nigeria 
illustrated this point, with results showing 
that the main predictor of treatment 
expenses was the cost of the antipsychotic 
agents’ used(39, 45). 
 
In this study, the most significant reduction 
in medical service utilization cost was 
hospitalization. The common reason for 
hospitalization was relapse among 
schizophrenic patients, (46-49) with the 
reduction of hospitalization after switching 
to risperidone, this indicated that relapse has 
reduced and patients were able to have a 
better quality of life and be productive for 
their community. Several studies had also 
demonstrated lower risk of relapse with 
risperidone use compared with typical 
antipsychotic drugs such as haloperidol (1, 
12). It has been estimated that risk of relapse 
in patients with schizophrenia was 3.5% per 
month(27). Repeated relapses might 
adversely affect future remission, level of 
disability, and heighten treatment 
resistance(50-53). Thus risperidone was 
superior in preventing relapse and providing 
important clinical benefits to patient and 
cost-savings due to fewer rehospitalization.  
 
All functional parameters such as 
institutionalized residential care, 
employment, violent episodes, suicide 
attempts and police reports at least once 
showed improvement during treatment with 
risperidone. Further, when unemployment 
and suicide attempts during the two 
treatment periods were analyzed as lost 
productivity and valued in terms of per 
capita income, the economic loss during 
treatment with typical antipsychotic drugs 
were higher than costs associated with 
risperidone treatment. The percentage of 
employment with risperidone treatment in 
this study (64.3%) was higher than 2004 
employment rates (48%) gathered by the 
Malaysian National Mental Health Registry 
among patients with schizophrenia(54). 
However as overall particularly in Malaysia, 
the social stigma attached to mental illnesses 
limited the employment opportunities of 
patients with schizophrenia(55, 56). 
 
The findings in this study can be utilized for 
future implementation of National 
Healthcare Financing in Malaysia and 
strengthening the insurance coverage for 
patients with mental illness. This study 
provided information for the ability of 
patients and family members to pay out-of-
pocket for the antipsychotic medication and 
utilization of medical services. Although the 
costing of this study for both treatments 
were only based on hospital charges, not the 
analysis of hospital costs based on direct and 
indirect cost, the decision on healthcare 
financing and insurance coverage not only 
aiming at cost-saving, the policy maker 
should also consider patients’ well being and 
the quality of life, and beyond the calculated 
hospital costs. The findings on functional 
parameters in this study has proved that the 
social and economic gain were vast more 
with risperidone than typical antipsychotics.     
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There were limitations to the present study 
that should be taken into consideration when 
interpreting the results. Although this study 
utilized secondary data from patients’ 
medical record, recalled bias was overcome. 
There would be selection bias of the 
participant, as only subjects with complete 
information for one year with typical 
antipsychotic and later one year with 
risperidone were selected. Subjects who had 
been treatment less than one year for both 
treatments might have more information 
regarding medical service utilization and 
functional parameters. The results for this 
group can be interpreted as cost of treatment 
per month. The cost of concomitant 
treatment should be included in the cost of 
medication because the information was 
available in the medical record.           
  
Conclusions 
 
The present study suggested that switching 
to risperidone after treatment failure or 
treatment intolerance of previous typical 
antipsychotic agents might provide clinical 
advantages, but not the cost of treatment. 
Further studies were required to investigate 
the relationship between the apparent 
clinical benefit and cost limitations of 
risperidone use. The findings will clarify the 
real impact of newer antipsychotic agents on 
mental health patients in developing 
countries. 
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